Trial Profile
Retrospective study of long term survival in patients with metastatic melanoma treated with vemurafenib or ipilimumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Sep 2018
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 07 Sep 2018 New trial record